José Juan Pérez Morán-rekin lankidetzan egindako argitalpenak (21)

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2016

  1. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 61-72

  2. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2015

  1. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  2. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

  3. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

    Haematologica, Vol. 100, Núm. 2, pp. e53-e55

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

  2. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

    Leukemia, Vol. 26, Núm. 9, pp. 1986-2010

  3. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2011

  1. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features

    Haematologica, Vol. 96, Núm. 2, pp. 328-332

  2. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2009

  1. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

    American Journal of Hematology, Vol. 84, Núm. 3, pp. 149-152

  2. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients

    Haematologica, Vol. 94, Núm. 11, pp. 1599-1602

  3. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

    Blood, Vol. 114, Núm. 20, pp. 4369-4372

2008

  1. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

    Blood, Vol. 112, Núm. 10, pp. 4017-4023

2007

  1. Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia

    British Journal of Haematology, Vol. 136, Núm. 1, pp. 114-116

  2. Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia

    Clinical Lymphoma and Myeloma, Vol. 7, Núm. 9, pp. 573-579

2005

  1. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 68-72

2003

  1. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value

    Blood, Vol. 101, Núm. 12, pp. 4695-4700